CN1056144C - 6－杂环－4－氨基－1,3,4,5－四氢苯并[cd]吲哚类化合物的新用途 - Google Patents

6－杂环－4－氨基－1,3,4,5－四氢苯并[cd]吲哚类化合物的新用途 Download PDF

Info

Publication number
CN1056144C
CN1056144C CN93114191A CN93114191A CN1056144C CN 1056144 C CN1056144 C CN 1056144C CN 93114191 A CN93114191 A CN 93114191A CN 93114191 A CN93114191 A CN 93114191A CN 1056144 C CN1056144 C CN 1056144C
Authority
CN
China
Prior art keywords
indoles
amino
solution
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN93114191A
Other languages
English (en)
Chinese (zh)
Other versions
CN1094724A (zh
Inventor
R·N·布赫
M·E·弗劳
D·E·罗霍恩
小·C·J·帕盖特
J·M·肖斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1094724A publication Critical patent/CN1094724A/zh
Application granted granted Critical
Publication of CN1056144C publication Critical patent/CN1056144C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
CN93114191A 1992-09-30 1993-09-29 6－杂环－4－氨基－1,3,4,5－四氢苯并[cd]吲哚类化合物的新用途 Expired - Fee Related CN1056144C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US954,105 1992-09-30
US07/954,105 US5364856A (en) 1991-03-28 1992-09-30 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[CD]indoles

Publications (2)

Publication Number Publication Date
CN1094724A CN1094724A (zh) 1994-11-09
CN1056144C true CN1056144C (zh) 2000-09-06

Family

ID=25494930

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93114191A Expired - Fee Related CN1056144C (zh) 1992-09-30 1993-09-29 6－杂环－4－氨基－1,3,4,5－四氢苯并[cd]吲哚类化合物的新用途

Country Status (15)

Country Link
US (10) US5364856A (enExample)
EP (2) EP1000621A3 (enExample)
JP (1) JPH06211655A (enExample)
KR (1) KR940006584A (enExample)
CN (1) CN1056144C (enExample)
AU (1) AU676849B2 (enExample)
CA (1) CA2107010A1 (enExample)
CZ (1) CZ9302010A3 (enExample)
HU (1) HUT66076A (enExample)
IL (1) IL107125A (enExample)
MX (1) MX9305998A (enExample)
NO (1) NO933477L (enExample)
RU (1) RU2138262C1 (enExample)
TW (1) TW248558B (enExample)
ZA (1) ZA937153B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633273A (en) * 1991-03-28 1997-05-27 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz[cd] indoles
US5347013A (en) * 1991-03-28 1994-09-13 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz[cd]indoles
TW248556B (enExample) * 1993-01-18 1995-06-01 Takeda Pharm Industry Co
US5385928A (en) * 1994-05-18 1995-01-31 Eli Lilly And Company Tetrahydrobenz [CD] indazoles, compositions and use
US5990114A (en) * 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
EP1083918A1 (en) * 1998-06-08 2001-03-21 Advanced Medicine, Inc. Novel therapeutic agents that modulate 5-ht receptors
WO2000073277A1 (en) * 1999-06-02 2000-12-07 Ishihara Sangyo Kaisha, Ltd. Fused tricyclic compounds, process for their preparation, and herbicidal compositions containing them
US6770596B1 (en) 2000-04-21 2004-08-03 Ishihara Sangyo Kaisha Ltd. Fused tricyclic compounds, process for their preparation, and herbicidal compositions containing them
RU2197961C2 (ru) * 2000-07-17 2003-02-10 Центр по разработке эластомеров Казанского государственного технологического университета Средство для профилактики и купирования тошноты и рвоты
KR20140145141A (ko) 2012-03-30 2014-12-22 클래리언트 다이아그노스틱 서비시즈, 인크. 생물학적 샘플의 영상 생성 방법
CN111265268A (zh) * 2018-12-05 2020-06-12 苏州英途康医疗科技有限公司 医疗器械

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0371246A1 (en) * 1988-10-21 1990-06-06 FARMITALIA CARLO ERBA S.r.l. Antiemesis ergoline derivatives
CN1066072A (zh) * 1991-03-28 1992-11-11 伊莱利利公司 6-杂环-4-氨基-1，3，4，5-四氢苯并[cd]吲哚

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3194811A (en) * 1963-09-05 1965-07-13 Merck & Co Inc Aroyl-benzindolyl acids
BE755270A (fr) * 1969-08-27 1971-02-25 Sandoz Sa Nouveaux derives du benzo(cd)indole, leur preparation et medicaments contenant ces derives
BE757879A (fr) * 1969-10-24 1971-04-22 Sandoz Sa Derives du benzo(cd)indole, leur preparation et medicaments contenant ces derives
CH517732A (de) * 1969-10-24 1972-01-15 Sandoz Ag Verfahren zur Herstellung neuer Guanidin- Verbindungen
FI206974A7 (enExample) * 1973-07-16 1975-01-17 Sandoz Ag
US4110339A (en) * 1977-11-25 1978-08-29 Eli Lilly And Company 4-(Di-n-propyl)amino-1,3,4,5-tetrahydrobenz[cd]indole
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
US4282240A (en) * 1979-11-23 1981-08-04 Merck & Co., Inc. Amino substituted tetrahydrobenzindoles
FR2510111A1 (fr) * 1981-07-24 1983-01-28 Roussel Uclaf Nouveaux derives du piperidin-3-yl indole, leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
FR2522658A1 (fr) * 1982-03-05 1983-09-09 Roussel Uclaf Application a titre de medicaments de derives du trans 4-amino benz (c,d) indol-5-ol ainsi que de leurs sels, compositions les renfermant, nouveaux derives et leur procede de preparation
JPS5969151A (ja) * 1982-10-13 1984-04-19 Unitika Ltd 球状イオン交換樹脂とその製造法及び吸着処理法
DE3346573A1 (de) * 1983-12-23 1985-07-04 Troponwerke GmbH & Co KG, 5000 Köln 1,3,4,5-tetrahydrobenz(c,d)indole, ein verfahren zu ihrer herstellung und ihre verwendung
US4576959A (en) * 1984-02-06 1986-03-18 Eli Lilly And Company 6-Substituted-4-dialkylaminotetrahydrobenz[c,d]indoles
US4983622A (en) * 1984-02-06 1991-01-08 Eli Lilly And Company 6-substituted-4-dialkylaminotetrahydrobenz(c,d)indoles
IL74222A (en) * 1984-02-06 1988-07-31 Lilly Co Eli 6-substituted-4-dialkylamino tetrahydrobenz(c,d)indoles,their preparation and pharmaceutical compositions comprising them
CA1266482A1 (en) * 1984-05-24 1990-03-06 Carl Kaiser 6-oxygenated-1,3,4,5-tetrahydrobenz(cd)indol-4-amines
DE3525564A1 (de) * 1985-07-15 1987-02-05 Schering Ag Tricyclische verbindungen mit indolstruktur, verfahren zu ihrer herstellung und deren verwendung als arzneimittel
US4745126A (en) * 1987-03-12 1988-05-17 Eli Lilly And Company Method of treating anxiety with tetrahydrobenz[c,d]indole-6-carboxamides
US4943428A (en) * 1987-07-10 1990-07-24 Wright State University Stimulation of serotonin-1A receptors in mammals to alleviate motion sickness and emesis induced by chemical agents
DE3809155A1 (de) * 1988-03-18 1989-09-28 Bayer Ag 1,3,4,5-tetrahydrobenz-(c,d)-indole
US5204340A (en) * 1989-04-11 1993-04-20 Eli Lilly And Company Tetrahydrobenz(c,d)indole serotonin agonists
US4977172A (en) * 1989-09-29 1990-12-11 Warner-Lambert Company Method of treating the symptoms of cognitive decline in an elderly patient employing (S)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)-methyl]-2-oxazolidinone
US5302612A (en) * 1990-02-26 1994-04-12 Eli Lilly And Company 6-substituted-hexahydrobenz[cd]indoles
US5039820A (en) * 1990-02-26 1991-08-13 Eli Lilly And Company 4-amino-6-iodo-hexahydrobenz(cd)indoles
TW219933B (enExample) * 1990-02-26 1994-02-01 Lilly Co Eli
US5212319A (en) * 1990-02-26 1993-05-18 Eli Lilly And Company Intermediates to 4-amino-hexahydrobenz[cd]indoles and processes therefor
US5397779A (en) * 1990-06-15 1995-03-14 Roussel-Uclaf Cephalosporins
US5229410A (en) * 1990-08-15 1993-07-20 Eli Lilly And Company 6-substituted-hexahydrobenz[cd]indoles
US5633273A (en) * 1991-03-28 1997-05-27 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz[cd] indoles
US5347013A (en) * 1991-03-28 1994-09-13 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz[cd]indoles
US5266571A (en) * 1992-01-09 1993-11-30 Amer Moh Samir Treatment of hemorrhoids with 5-HT2 antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0371246A1 (en) * 1988-10-21 1990-06-06 FARMITALIA CARLO ERBA S.r.l. Antiemesis ergoline derivatives
CN1066072A (zh) * 1991-03-28 1992-11-11 伊莱利利公司 6-杂环-4-氨基-1，3，4，5-四氢苯并[cd]吲哚

Also Published As

Publication number Publication date
AU4868293A (en) 1994-07-14
NO933477L (no) 1994-04-05
HU9302749D0 (en) 1993-12-28
US5665743A (en) 1997-09-09
US5674884A (en) 1997-10-07
AU676849B2 (en) 1997-03-27
US5750554A (en) 1998-05-12
NO933477D0 (no) 1993-09-29
CZ9302010A3 (en) 1994-05-18
ZA937153B (en) 1995-03-27
EP0590971A1 (en) 1994-04-06
MX9305998A (es) 1995-01-31
US5643930A (en) 1997-07-01
IL107125A0 (en) 1993-12-28
US5736562A (en) 1998-04-07
HUT66076A (en) 1994-09-28
TW248558B (enExample) 1995-06-01
US5641797A (en) 1997-06-24
IL107125A (en) 1998-09-24
KR940006584A (ko) 1994-04-25
EP1000621A3 (en) 2003-05-14
RU2138262C1 (ru) 1999-09-27
US5624944A (en) 1997-04-29
CN1094724A (zh) 1994-11-09
EP1000621A2 (en) 2000-05-17
CA2107010A1 (en) 1994-03-31
JPH06211655A (ja) 1994-08-02
US5594019A (en) 1997-01-14
US5364856A (en) 1994-11-15
US5665758A (en) 1997-09-09

Similar Documents

Publication Publication Date Title
CN1059210C (zh) 制备6－杂环－4－氨基－1,3,4,5－四氢苯并[cd]吲哚及其可作药用的酸加成盐的方法
CN1254474C (zh) 作为多巴胺D<sub>3</sub>受体调节剂(精神抑制药)的四氢苯并氮杂䓬衍生物
CN1065244C (zh) 三环苯并氮杂䓬加压素拮抗剂
CN1247588C (zh) 腺苷A2a受体拮抗剂
CN1113236A (zh) 非肽基速激肽受体拮抗剂
CN1251589A (zh) 为gaba受体配位体的取代的三唑并哒嗪衍生物
CN1190432C (zh) 作为5－htib拮抗药的哌嗪衍生物
CN1946714A (zh) 用作多巴胺d3受体调节剂的氮杂二环(3.1.0)已烷衍生物
CN1522249A (zh) 作为神经肽y受体的配体的喹啉衍生物
CN1097753A (zh) 五员杂环、制备方法以及含有这些化合物的药物组合物
CN1684964A (zh) 一些新的咪唑并吡啶及其用途
CN1056144C (zh) 6－杂环－4－氨基－1,3,4,5－四氢苯并[cd]吲哚类化合物的新用途
CN1404479A (zh) 新的1,3－二氢－2h－吲哚－2－酮衍生物,它们的制备方法以及含有它们的药物组合物
CN1568187A (zh) 2h－2,3－二氮杂萘－1－酮和其使用方法
CN1208412A (zh) 促性腺激素释放激素拮抗剂
CN1053429A (zh) 吲哚取代五元芳杂环化合物
CN1656082A (zh) 蛋白激酶抑制剂
CN1703401A (zh) 黑色素浓集激素受体的配体:取代的1－苄基－4－芳基哌嗪类似物
CN1073174A (zh) 杂环衍生物
CN1726216A (zh) C－6修饰的吲唑基吡咯并三嗪
CN1142492A (zh) 用作抗糖尿病剂的取代n-(吲哚-2-羰基)甘氨酰胺及其衍生物
CN1596253A (zh) 用作抗炎药的螺－乙内酰脲化合物
CN1260781A (zh) 具有综合的5ht1a、5ht1b和5ht1d受体拮抗剂活性的吲哚衍生物
CN1553909A (zh) 作为gaba受体配体的苯并咪唑和吡啶并咪唑衍生物
CN1041941A (zh) 苯并二氮杂衍生物的制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee